Bulletin
Investor Alert

Market Pulse Archives

June 17, 2021, 6:45 a.m. EDT

CureVac tumbles 41% in premarket on COVID-19 vaccine disappointment

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    CureVac N.V. (CVAC)
  • X
    Pfizer Inc. (PFE)
  • X
    BioNTech SE ADR (BNTX)

or Cancel Already have a watchlist? Log In

By Barbara Kollmeyer

Shares of CureVac /zigman2/quotes/219999729/composite CVAC -5.01% fell 42% in premarket trading on Thurdsay, a day after the German biotech said its COVID-19 vaccine was 47% effective in preventing the disease. CureVac's study, conducted in 10 countries and involving 40,000 people, showed the vaccine's struggle against a "fast changing environment" of at least 29 COVID-19 variants, with the original coronavirus strain "almost completely absent." Efficacy rates were at 90% for competing candidates of CureVac's messenger RNA-based vacine from Pfizer /zigman2/quotes/202877789/composite PFE +0.05% and BioNTech /zigman2/quotes/214419716/composite BNTX +5.04% and Moderna /zigman2/quotes/205619834/composite MRNA +2.30% . Millions have already been vaccinated with those.

/zigman2/quotes/219999729/composite
US : U.S.: Nasdaq
$ 49.26
-2.60 -5.01%
Volume: 752,087
July 30, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$9.17 billion
Rev. per Employee
$100,563
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 42.81
+0.02 +0.05%
Volume: 24.76M
July 30, 2021 4:03p
P/E Ratio
18.33
Dividend Yield
3.64%
Market Cap
$239.64 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 328.35
+15.76 +5.04%
Volume: 4.03M
July 30, 2021 4:00p
P/E Ratio
58.10
Dividend Yield
N/A
Market Cap
$79.30 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 353.60
+7.96 +2.30%
Volume: 11.35M
July 30, 2021 4:00p
P/E Ratio
281.98
Dividend Yield
N/A
Market Cap
$141.98 billion
Rev. per Employee
$617,996
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.